ARCHIVES

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

This article is from The Cancer Letter archive.

Vol. 01 No. 30 | July 25, 1975

Download PDF Visit The Full Archive

Related Articles

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012

DCE Board Sets Aside $2 Million For Radiation Grants Program; Okays Concept For Add-On To ASCUS Trial

October 13, 1995

DCT Advisors Approve Increased Spending On Trials Monitoring

May 6, 1994

Study Finds Up To 12 Percent Of Specimens Misdiagnosed

October 28, 2005

DCCP Board Okays Concept Of Study On Black/White Survival Differences

March 5, 1982

New Ultrasound Technique For Hard To Diagnose Cysts

June 29, 2001